Annovis raises $10 million to fund alzheimer's drug through phase 3 trial
Tweet Send to a Friend
Annovis Bio Inc. (NYSE: ANVS) closed a $10 million underwritten public offering to fund operations through the second quarter of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
